Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics by McEvoy, Joseph et al.
 Lipidomics Reveals Early Metabolic Changes in Subjects with
Schizophrenia: Effects of Atypical Antipsychotics
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation McEvoy, Joseph, Rebecca A. Baillie, Hongjie Zhu, Peter Buckley,
Matcheri S. Keshavan, Henry A. Nasrallah, George G. Dougherty,
Jeffrey K. Yao, and Rima Kaddurah-Daouk. 2013. “Lipidomics
Reveals Early Metabolic Changes in Subjects with Schizophrenia:
Effects of Atypical Antipsychotics.” PLoS ONE 8 (7): e68717.
doi:10.1371/journal.pone.0068717.
http://dx.doi.org/10.1371/journal.pone.0068717.
Published Version doi:10.1371/journal.pone.0068717
Accessed February 19, 2015 2:02:56 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717620
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Lipidomics Reveals Early Metabolic Changes in Subjects
with Schizophrenia: Effects of Atypical Antipsychotics
Joseph McEvoy1, Rebecca A. Baillie2, Hongjie Zhu1, Peter Buckley3, Matcheri S. Keshavan4, Henry A.
Nasrallah5, George G. Dougherty7, Jeffrey K. Yao6,7, Rima Kaddurah-Daouk1*
1 Duke University Medical Center, Department of Psychiatry and Behavioral Sciences, Durham, North Carolina, United States of America, 2 Rosa & Co LLC,
San Carlos, California, United States of America, 3 Medical College of Georgia, Augusta, Georgia, United States of America, 4 Beth Israel Deaconess Medical
Center and Harvard Medical School, Boston, Massachusetts, United States of America, 5 University of Cincinnati College of Medicine, Cincinnati, Ohio, United
States of America, 6 VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States of America, 7 Department of Psychiatry, University of Pittsburgh
School of Medicine, Pittsburgh, Pennsylvania, United States of America
Abstract
There is a critical need for mapping early metabolic changes in schizophrenia to capture failures in regulation of
biochemical pathways and networks. This information could provide valuable insights about disease mechanisms,
trajectory of disease progression, and diagnostic biomarkers. We used a lipidomics platform to measure individual
lipid species in 20 drug-naïve patients with a first episode of schizophrenia (FE group), 20 patients with chronic
schizophrenia that had not adhered to prescribed medications (RE group), and 29 race-matched control subjects
without schizophrenia. Lipid metabolic profiles were evaluated and compared between study groups and within
groups before and after treatment with atypical antipsychotics, risperidone and aripiprazole. Finally, we mapped lipid
profiles to n3 and n6 fatty acid synthesis pathways to elucidate which enzymes might be affected by disease and
treatment. Compared to controls, the FE group showed significant down-regulation of several n3 polyunsaturated
fatty acids (PUFAs), including 20:5n3, 22:5n3, and 22:6n3 within the phosphatidylcholine and
phosphatidylethanolamine lipid classes. Differences between FE and controls were only observed in the n3 class
PUFAs; no differences where noted in n6 class PUFAs. The RE group was not significantly different from controls,
although some compositional differences within PUFAs were noted. Drug treatment was able to correct the aberrant
PUFA levels noted in FE patients, but changes in re patients were not corrective. Treatment caused increases in both
n3 and n6 class lipids. These results supported the hypothesis that phospholipid n3 fatty acid deficits are present
early in the course of schizophrenia and tend not to persist throughout its course. These changes in lipid metabolism
could indicate a metabolic vulnerability in patients with schizophrenia that occurs early in development of the disease.
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Introduction
Schizophrenia is a serious psychiatric brain disorder with a
worldwide prevalence of about 1% [1]. Due to its early age of
onset, schizophrenia has a large socioeconomic impact, with
long-term disability and associated caretaking costs [2].
Previous work had implicated neurotransmitters and receptors
in the pathophysiology of schizophrenia; thus, most therapeutic
drug development has targeted dopamine, serotonin, and
glutamate systems. Antipsychotics, which work by blocking
dopamine, are highly effective in treating psychosis, but the
vast majority of individuals discontinue treatment over time,
due to lack of effectiveness or development of side effects;
furthermore, not all patients respond similarly to those
medications [3].
Schizophrenia is linked to a high prevalence of comorbid
medical disorders. For example, diabetes is 2 to 4 times more
prevalent in patients with schizophrenia than in the general
population [4,5]. Many medical disorders, including metabolic
syndrome, obesity, diabetes, and cardiovascular disease, are
characterized by changes in lipid metabolism. Moreover,
several antipsychotic drugs, particularly those that target
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dopamine and serotonin receptors (e.g., clozapine and
olanzapine), can cause adverse effects that are related to lipid
metabolism, including weight gain, insulin resistance, and
hypertriglyceridemia [6]. However, other drugs have reduced
side effects; for example, a 26-week randomized clinical trial
tested 317 patients with schizophrenia and found that
aripiprazole (ARI) was associated with less weight gain and
smaller increases in total cholesterol/triacylglycerol than
olanzapine [7].
It is not clear whether patients with schizophrenia are
predisposed to metabolic disorders (i.e., before treatment) or
whether these disorders are primarily a treatment effect.
Accordingly, several studies have focused on patients with first
episodes of schizophrenia to investigate whether patients with
no drug exposure were more likely to have developed a
metabolic disorder than controls. However, those studies
showed inconsistent results [8,9].
In recent decades, several studies have shown that
phospholipids were impaired in schizophrenia [10,11].
Phospholipids play a critical role in the structure and function of
membranes (including synaptic vesicle membranes); therefore,
changes in membrane lipids might directly affect
neurotransmission [12,13]. In a previous study, we found
evidence that atypical antipsychotics had peripheral lipid
effects [11]. We found that schizophrenia was associated with
major defects in polyunsaturated fatty acid (PUFA)
compositions in phosphatidylethanolamine (PE) and
phosphatidylcholine (PC) lipid classes. In addition, PE
synthesis was reduced in schizophrenia. We also found that
treatment with antipsychotic drugs partially reversed the deficits
in PE concentrations observed in patients with schizophrenia.
Moreover, different drugs affected different lipids; for example,
olanzapine and risperidone (RIS) affected a much broader
range (~50 lipids) than ARI.
The most functionally significant lipids are PUFAs, which
comprise two main classes: those with the first double bond at
the 3rd carbon atom (n3 PUFAs) and those with the first double
bond at the 6th (n6 PUFAs) carbon atom, counting from the
methyl end of the fatty acid chain. Both n3 and n6 fatty acids
are abundantly found in the brain [14]. In particular, arachidonic
acid (n6), dihomogamma-linolenic acid (n6), and
eicosapentaenoic acid (EPA, n3) are important in cell-signaling
and enzyme-regulation, and they serve as precursors for
eicosanoids (prostaglandins, thromboxanes, and leukotrienes).
The n6 fatty acids, like arachidonic acid, tend to promote
inflammatory conditions [15]. In contrast, the n3 fatty acids tend
to reduce the rate of inflammatory molecule production.
The first aim of the present study was to investigate which
lipid changes were associated with schizophrenia, early in the
disease, and which developed after taking antipsychotic drugs,
later in the disease. A second aim was to determine where in
the lipid synthesis pathway these effects occurred. We
examined lipid profiles derived from the lipidomics platform.
Then, we examined the changes in lipids that occurred after 2
weeks of antipsychotic treatment (RIS or ARI) for
schizophrenia.
Methods
This study was approved by the Duke University Institutional
Review Board. Written, informed consent was obtained from all
subjects or legal guardians. Clinicians were blinded to the
laboratory data, and laboratory assessments were carried out
blinded to diagnostic assignments of the subjects.
Selection criteria
Patients.  The subjects presented here have been described
previously [16]. Briefly, 20 subjects were medication-naïve, and
they had presented for treatment at the Jon Umstead Hospital
for treatment (FE group). Another 20 subjects had presented
for treatment of a psychotic relapse of schizophrenia (defined
by DSM-IV) or schizoaffective disorder, related to their non-
adherence to a prescribed outpatient treatment (RE group). No
patient’s medication was discontinued as a condition for
participation in the study. All available information from
patients, family members, and treating clinicians indicated that
each patient in the RE group had taken no antipsychotic
medication for at least the preceding 2 weeks, and in most
cases, much longer. All patients had at least two Positive
symptom items rated > 4 at baseline on the Brief Psychiatric
Rating Scale (BPRS) [17]. BPRS scores were also rated at the
end of the study. Blood samples were collected before and
after treatment with either ARI (n = 19) or RIS (n = 21).
Control group.  We recruited race-matched, healthy control
subjects (HC group) from the same communities as the
subjects; they included hospital staff and their family members
and friends (n = 29). Control subjects had no personal history
of psychotic illness and no first or second degree relatives with
psychotic illnesses.
Antipsychotic treatment
All patients were randomized to receive one of two
medications, RIS or ARI. The drugs were given to
approximately equal subsets within both groups (FE and RE).
The dose of antipsychotic medication for each individual was
based on the judgment of a physician. RIS doses ranged from
1 to 6 mg/day, and ARI doses ranged from 5 to 30 mg/day.
Subjects received treatment for approximately 2 weeks.
Lipid sampling
All blood samples were collected in the early morning after
overnight fasting. Baseline samples were drawn prior to
starting antipsychotic treatment for the study. Subjects that had
received any antipsychotic treatment during the referral
process (e.g., due to agitation in an emergency department)
were maintained untreated for 2–3 days before the baseline
plasma sample was drawn. Follow-up samples were drawn
after approximately 2 weeks of treatment, before discharge
from the clinic.
Plasma lipid profiles were assessed (Lipomics Technologies,
West Sacramento, CA) as described previously [18]. Briefly,
plasma lipids were extracted, lipid classes isolated, and
individual fatty acids within each lipid class quantified [19]. The
analyses were based on concentrations (nmol/g plasma) of n3
and n6 free fatty acids and the numbers of individual n3 and n6
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fatty acids contained in the phospholipids, PC and PE.
Metabolites were designated names that reflected the lipid
class and the fatty acid structure, e.g., palmitic acid in
phosphatidylcholine was designated PC16: 0.
Statistical analyses
For all variables, a correlation test for the hypothesis of
normality was rejected for one or more of the groups at p<0.05
[20]. No common transformations altered this conclusion; thus,
the data were found not to be approximately normal. Hence, all
group pair-wise differences in lipid concentrations and product/
precursor ratios were tested with Wilcoxon rank sum tests,
except when comparing variables with covariate dependence.
Covariates.  The demographic data in Table 1 shows that
the FE and RE groups were not well-matched for gender with
the HC group. Also, the FE group was not well-matched for age
with the RE and HC groups. The group-effects can be
confounded by these demographic covariates when both an
imbalance is present across groups and the lipid variable is
dependent on the covariate. Therefore, the possibility of
confounding was addressed by checking Kendall’s tau rank
correlations between each lipid and the covariates. Relevant
covariates and interactions were first identified for each lipid
variable using all three subject groups combined. The Pr(tau)
was determined, under the null hypothesis of zero correlation
between a given lipid variable and any covariate. Covariates
included Age, Sex, Race, body mass index (BMI), Sex×Age
(where × indicates an interaction between variables),
Race×Sex, Race×Age, Race×Sex×Age, BMI×Sex, BMI×Race,
and BMI×Sex×Race. Age and BMI were collinear; therefore,
the covariate Age×BMI was not included. When the Pr(tau) <
0.05, the covariate effect on the lipid variable was separated
from the group effect on this variable with a nonparametric
analysis of covariance (nANCOVA), based on a rank-
transformation procedure [21,22]. Thus, low nANCOVA p-
values represented significant differences after adjusting for
covariate dependencies. This rank-based method can capture
monotonic nonlinear as well as linear covariate dependence.
Furthermore, when all covariate interactions are included, it
provides a conservative result when the lipid dependence upon
a group is indistinguishable from the dependence upon a
covariate due to covariate imbalances between groups.
Therefore, we adjusted for all relevant covariates, and the
differences between subject groups represent effects primarily
due to disease or treatment.
Lipid pathway analysis.  Fatty acid product/precursor ratios
were analyzed within each fatty acid synthesis pathway (n3 or
n6), when they corresponded to a pure elongase or desaturase
enzymatic reaction step [23]. However, precursors were not
considered when over 10% of zeros (i.e., infinite ratios) were
present within any subject group; otherwise, ratios with a value
of 0 for the precursor were given the highest rank in our rank-
based analysis.
Lipid concentration comparisons among
groups.  Corrections for multiple tests were set by assigning
α=0.05 to each fatty acid pathway (i.e., n3 and n6) within each
lipid class (i.e., PC, PE) and group comparison (HC vs. FE, HC
vs. RE, FE vs. RE). The Bonferroni correction was applied for
the number of fatty acid variables (B) within the particular
pathway of interest. Differences between subject and control
groups were considered significant at p<0.05/B, and they were
considered trends at p<0.10/B, based on the Wilcoxon Rank
Sum Test or McSweeney-Porter nANCOVA. Differences
between pre- and post treatment values within a group were
considered significant at p<0.05/B, and trends at p<0.10/B,
based on the Wilcoxon Signed Ranks Test. Exploratory
analyses, with larger numbers of tests, used both the
conservative Bonferroni correction of alpha and control of the
False Discovery Rate (FDR) [24,25]. Our lipid measures were
not independent, but overwhelmingly exhibited positive
monotonic mutual dependencies.
Results
For the first set of analyses, samples from all 40 subjects
with schizophrenia (FE + RE subjects) were compared with 29
race-matched HC subjects (Table 1). There were no significant
differences in height, weight, BMI, or waist circumference
between FE and RE groups. The HC group had significantly
greater weight and BMI than the FE group. Age was not
significantly different between the RE and HC groups.
However, as expected, the FE group was significantly younger
than both the HC (t-test, p=0.0014)) and RE (t-test, p= 0.01)
groups. Also, as expected, the FE group had a lower mean
total BPRS score (t-test, p=0.03) at enrollment than the RE
group. The two subject groups (FE and RE) had similar gender
compositions, but they were different from the gender
composition of the HC group.
No demographic differences were found between the ARI
and RIS treatment groups (not shown).
Table 1. Demographics of subjects without (controls) or
with schizophrenia (FE and RE), measured before (initial)
and after (final) drug treatment.
 Controls (n=29)FE + RE (n=40)FE (n=20) RE (n=20)
% Female 79.3* 27.5 35 20
% African American 82.7 72.5 65 80
Age (y) 41.0±9.5 31.8±12.2 27.0±9.8* 36.7±12.7
Height (in) 66.6±3.3 67.7±4.1 66.8±3.8 68.6±4.3
Weight (lbs) initial 186.1±48.7a 156.2±32.8 149.1±31.8 163.3±33.0
BMI (kg/m2) initial 29.4±7.0a 24±. 05.0 23.4±4.3 24.6±5.7
Waist circumference
(in) initial 38.7±7.1 35.0±4.7 34.2±5.0 35.9±4.4
Weight (lbs) final  159.9±33 153.1±31.9 166.6±33.5
BMI (kg/m2) final  24.6±5.1 24.1±4.4 25.1±5.7
Waist circumference
(in) final  36.1±5.1 35.1±5.4 37.1±4.7
BPRS initial  36.6±5.4 34.8±5.3b 38.4±5
BPRS final  25.6±6.4 22.8±5.9 28.4±5.8
Days treated  16.9±5.6 16.45±5.4 17.4±5.8
Values represent the mean ± standard deviation. FE, RE: patients with first
episode or recurrent schizophrenia, respectively. BMI: body mass index. BPRS:
Brief Psychiatric Rating Scale. *p<0.05, significantly different from the other two
groups. ap<0.05, Controls compared to FE; bp<0.05, FE compared to RE
Lipidomics of First-Time and Chronic Schizophrenia
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Linear regression analyses between the changes in the
BPRS scores with drug treatment and changes in BMI, body
weight, and waist circumferences showed correlation
coefficients of 0.18409, -0.21112, and -0.03309, respectively.
This indicated that the effect of drugs on disease severity
(BPRS score) was not significantly correlated with the drug
effects on subject characteristics.
Metabolic Signature of Disease
The overall lipid classes at baseline were compared between
subjects and controls (Table 2) and between subject groups. At
baseline, the plasma concentrations of major lipid classes were
not significantly different between control subjects and subjects
with schizophrenia (FE + RE). There were no significant
differences between HC and FE, HC and RE, or FE and RE.
This was not surprising, because concentrations of the major
lipid classes do not necessarily reflect differences in lipid
composition, which depend on the individual lipid synthesis
pathways.
When we analyzed individual n3 and n6 lipids, we found
significant differences between study groups in the
compositions of PC and PE lipids (Table 3), both at baseline
and after treatment. At baseline, the FE and HC groups
showed significant differences in the PCn3 and PEn3
concentrations. In contrast, the FE and RE groups only showed
significant differences in the PEn3 concentrations. After
treatment, the PCn6, PEn3, and PEn6 concentrations were
altered in the FE group, but not in the RE group.
We next evaluated the individual n3 fatty acids (Figure 1
Table S1) incorporated in the individual PC and PE lipids. We
found that some metabolites were significantly different
between the HC group and the FE group before treatment
(Figure 1, yellow shading). This indicated alterations in lipid
metabolism that occurred early in schizophrenia. Drug
treatment resulted in significant changes (pre- vs.
postdifferences shown in green) in individual n3 lipids in the FE
group (PC 20:4n3, 20:5n3, 22:5n3; PE 20:5n3, 22:5n3,
22:6n3). In contrast, the HC group and the RE group at
baseline were not significantly different in n3 phospholipids
(Figure 1 Table S1). Furthermore, unlike the FE group, the RE
group showed little change in n3 phospholipids after drug
treatment. Only one n3 (PC22: 6n3) showed a significant
change with treatment in the RE group.
Table 2. Baseline lipid concentrations in seven lipid classes
for subjects without (controls) or with schizophrenia (FE and
RE).
Lipid
Class
HC nmol/g
median (1st
and 3rd
quartiles)
FE nmol/g
median (1st
and 3rd
quartiles)
RE nmol/g
median (1st
and 3rd
quartiles)
HC vs.
FE p-
value
HC vs.
RE p-
value
FE vs.
RE p-
value
CE 2862 (2466,3219)
2300 (2087,
2720)
2343 (2104,
2835) 0.676 0.597 0.524
LYPC 198.7 (160.5,232.7)
205.6 (188.2,
227.6)
189.9 (165.0,
231.3) 0.474 0.607 0.314
PC 1472 (1383,1592)
1400 (1275,
1665)
1349 (1269,
1742) 0.770 0.636 0.947
PE 140.9 (131.8,174.7)
153.6 (131.8,
163.4)
142.0 (117.5,
170.2) 0.485 0.581 0.552
TG 677.1 (504.3,906.2)
611.3 (472.3,
736.2)
771.4 (567.0,
1031) 0.380 0.437 0.157
DAG 34.31 (27.75,56.41)
31.71 (23.92,
38.07)
39.66 (35.01,
47.12) 0.231 0.474 0.044
FA 321.3 (244.0,575.7)
379.6 (231.4,
527.5)
421.2 (269.9,
489.4) 0.780 1.000 1.000
Concentrations represent median values (1st and 3rd quartiles) expressed in nmol/g
of plasma. HC: healthy controls; FE, RE: patients with first episode or recurrent
schizophrenia, respectively. Individual p-values for pair-wise comparisons were
based on the Wilcoxon rank sum test, or the McSweeney-Porter nonparametric
ANCOVA procedure (for analytes with covariate dependence), adjusted with the
Bonferroni correction of alpha: 0.05/21 = 0.0024. CE: Cholesteryl esters; LYPC:
lysophosphatidylcholine; PC: phosphatidylcholine; PE: phosphatidylethanolamine;
TG: triacylglycerols; DAG: diacylglycerols; FA: fatty acids.
Table 3. Lipid concentrations in Controls and Subjects with schizophrenia (FE and RE) at baseline (pretreatment) and after
antipsychotic treatment (post treatment).
Lipid
Controls
nmol/g
P values Baseline
comparisons, FE v. HC, FE
v.RE First Episode Recurrent Episode
   
Pre treatment
nmol/g
Post treatment
nmol/g
p-value, Pre v.
Post
Pre treatment
nmol/g
Post treatment
nmol/g
p-value, Pre v.
Post
PC.n3 155.6 0.0052, 0.0238 94.75 114.35 0.0484 122.6 121.7 0.1650
PC.n6 1293.5 0.1848, 0.6096 1051.05 1321.65 0.0056 1095.9 1206.1 0.1893
PE.n3 25 0.001a, 0.0032 15.45 21.35 0.0010* 23.4 20.9 0.2774
PE.n6 116 0.0696, 0.4217 86.25 115.85 0.0008* 99.1 103.05 0.7841
Concentrations represent median values (nmol/g of plasma); Controls or HC: healthy controls; First episode: drug-naïve patients with a first episode of schizophrenia;
Recurrent episode: patients that had discontinued medication, and presented with recurrent schizophrenia. a Trend difference between first episode and control groups,
McSweeney-Porter procedure, Bonferroni-corrected alpha for trends: p<0.10/63=0.0016; * significant difference, Wilcoxon signed ranks test, alpha adjusted with Bonferroni
correction for significance: p<0.05/21=0.0024. Lipid notation indicates the lipid class and the double bond position, e.g., PC.n3 includes n3 fatty acids associated with PC
phospholipids.
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We also evaluated the n6 fatty acids (Figure 2) incorporated
in the individual PC and PE lipids. We found that, at baseline,
no significant differences were detected between the FE and
the HC groups in the individual n6 fatty acids incorporated in
PCs and PEs (Figure 2, top). However, in the FE group, drug
treatment caused significant changes (pre vs. post) in the
individual n6 lipids (PC 18:2n6, 18:3n6, 20:2n6, 20:3n6,
22:5n6; PE 20:3n6, 20:4n6, 22:5n6). Similarly, at baseline, the
n6 phospholipids were not significantly different between the
RE and the HC groups (Figure 2, bottom). In the RE group,
drug treatment also caused significant changes, but in only two
n6 lipids (20:2n6 and 20:3n6).
Figure 1.  Alterations in plasma PC and PE n3 fatty acids in subjects with schizophrenia.  Individual lipid profiles were
compared between healthy controls (HC) and patients with (A) first episode (FE) or (B) recurrent (RE) schizophrenia (Yellow).
Significant differences between HC and subjects with schizophrenia at baseline (pre-treatment) (Green). Significant differences
within a group, before and after treatment. pre: pre-treatment values; post: post-treatment values. Lines indicate changes in
individual subjects due to treatment. Data are scaled as a fraction of the maximum value for that lipid over all groups (HC, FE, and
RE). Pale color intensity indicates a trend with corrected alpha values: p<0.10/7=0.014 (PE), p<0.10/6=0.017 (PC); strong color
intensity indicates significance with corrected alpha values: p<0.05/7=0.0071 (PE), p<0.05/6=0.0083 (PC). Significant differences
were evaluated as described in the Methods.
doi: 10.1371/journal.pone.0068717.g001
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To determine the implications of these findings, we
investigated whether the changes in n3 and n6 fatty acids
reflected changes in synthesis or degradation. We evaluated
various steps of the n3 and n6 fatty acid synthesis pathways by
examining the ratio of individual fatty acids that were
considered the product and precursor of each enzyme in the
synthesis pathway (Table 4). At baseline, only the FE and HC
groups showed differences in fatty acid concentrations. Figure
3 illustrates how these differences affected the different steps
in the n3 synthesis pathway. The highlighted fatty acids
represent ratios that were different in FE compared to HC
groups. For example, the ratio of PC22: 5n3 to PC20: 5n3 was
Figure 2.  Alterations in plasma PC and PE n6 fatty acids in subjects with schizophrenia.  Individual lipid profiles were
compared between healthy controls (HC) and patients with (A) first episode (FE) or (B) recurrent (RE) schizophrenia (Yellow).
Significant differences between HC and subjects with schizophrenia at baseline (pre-treatment) (Green). Significant differences
within a group, before and after treatment. Lines indicate changes in individual subjects due to treatment. pre: pre-treatment values;
post: post-treatment values. Data are scaled as a fraction of the maximum value for that lipid over all groups (HC, FE, and RE). Pale
color intensity indicates a trend with corrected alpha values: p<0.10/8=0.0125 (PE and PC); strong color intensity indicates
significance with corrected alpha values: p<0.05/8=0.00625 (PE and PC). Significant differences were evaluated as described in the
Methods.
doi: 10.1371/journal.pone.0068717.g002
Lipidomics of First-Time and Chronic Schizophrenia
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significantly different between FE at baseline (median ratio
=2.40) and HC (median ratio =1.53) (Wilcoxon Rank Sum Test,
with corrected alpha: p<0.05/[17*3]=0.00098). In contrast, no
differences in the fatty acid concentrations or ratios were
detected between RE and HC groups.
We then evaluated the drug-induced changes in the ratios of
fatty acid products to precursors in both the n3 and n6 fatty
acid synthesis pathways (Table 4). This analysis would
determine which enzymes were modulated by drug treatment.
We compared changes in lipids for patients treated with ARI to
those treated with RIS, and found no significant differences.
Therefore, we pooled the treatment data for further analyses.
Figure 4 illustrates how the drug-induced changes in n3 and n6
fatty acids affected the n3 and n6 synthesis pathways. The
highlighted fatty acids indicate those that were significantly
different before and after treatment. The fatty acid ratio
analyses showed that the antipsychotic treatments significantly
affected both the n3 and n6 fatty acid synthesis pathways for
both FE and RE groups.
Schizophrenia is associated with a high prevalence of
metabolic syndrome and with a state of chronic, low-grade
Table 4. Comparison of baseline PC and PE synthesis
pathways, based on product/precursor ratios of n3 and n6
lipids that represent enzymatic steps in controls (HC) and
patients with schizophrenia (FE and RE).
 Pretreatment Post treatment
Product/precursor HC ratio FE ratio RE ratio FE ratio RE ratio
PC      
22:6n3/22:5n3 3.977 3.418 3.707 2.474# 3.211#
20:5n3/20:4n3 7.167 7.292 7.867 4.944# 6.123
22.5n3/20.5n3 1.535 2.399* 1.804 1.712# 1.652
22:5n6/22:4n6 0.810 0.794 0.767 0.836 0.796
20:4n6/20:3n6 4.853 4.613 4.654 3.288# 3.710#
20:3n6/20:2n6 7.500 7.558 7.668 8.704 7.419
18:3n6/18:2n6 0.003 0.003 0.003 0.004 0.003
22:4n6/20:4n6 0.033 0.037 0.037 0.042 0.038
20:2n6/18:2n6 0.015 0.014 0.015 0.017# 0.017
PE      
22:6n3/22:5n3 3.882 3.226 4.054 2.594 3.262
22.5n3/20.5n3 3.133 3.829 3.050 3.00 3.342
22:5n6/22:4n6 0.636 0.639 0.652 0.850 0.743
20:4n6/20:3n6 15.137 15.269 15.500 12.375 12.105#
20:3n6/20:2n6 7.286 6.000 6.714 8.636 8.125
18:3n6/18:2n6 0.006 0.005 0.007 0.007 0.009
22:4n6/20:4n6 0.034 0.039 0.040 0.04 0.039
20:2n6/18:2n6 0.024 0.026 0.025 0.027 0.024
Values represent the medians of the concentration ratios measured at baseline in
the groups indicated. HC: healthy controls; FE, RE: patients with first episode or
recurrent schizophrenia, respectively. Group comparisons were evaluated with the
McSweeney p-value to account for covariate dependence, or with the Wilcoxon
Rank Sum test for lipids without covariate dependence. *p=0.00028, significantly
different from HC, based on Wilcoxon Rank Sum test p-value, after adjusting with
Bonferroni alpha: p<0.05/(17*3)=0.00098. #p<0.00058, significantly different from
pretreatment, based on Wilcoxon Rank Sum test p-value, after adjusting with
Bonferroni alpha: p<0.05/(17*2)=0.00147.
inflammation; moreover, these conditions might be interrelated
[26]. The n3 and n6 fatty acid synthesis pathways are important
for maintaining the balance between anti- and pro-inflammatory
conditions. Therefore, differences in the n3/n6 ratio contained
in lipids may influence the levels of low-grade inflammation (or
be a symptom of disease) in the different study groups. We
found that patients with FE had lower n3/n6 ratios than either
RE or HC groups. Furthermore, when patients with FE received
antipsychotic treatment, the n3/n6 ratios were restored to HC
levels. In contrast, the n3/n6 ratios were similar in the RE and
HC groups, and the ratios did not improve with treatment.
Our covariate analysis ensured that the effects we observed
were independent of differences in body weight and age. Thus,
it seems likely that the changes in fatty acid synthesis that we
observed were relevant to the stage of the disease.
Exploratory study of seven lipid classes
In addition to our primary focus, which was to study the n3
and n6 fatty acids within the major phospholipid classes (PC
and PE), we conducted an exploratory study to determine
whether the different study groups (at baseline) showed
differences in the fatty acid profiles for seven lipid classes, i.e.,
PC, PE, cholesteryl ester (CE), lysoPC (LYPC), triacylglycerol
(TAG), diacyglycerol, and free fatty acids (FFA). We compared
baseline profiles between FE and HC and between RE and
HC, but significant results were found only for the FE vs. HC
comparison. We used the 10% FDR control, which is generally
appropriate for exploratory work. In the FE group, 10 lipids
were present at lower concentrations in than in the HC group;
five involved 20:5n3 (in CE, PC, PE, TAG, and FFA classes);
two involved 22:5n3 (in PC and PE classes); and two involved
22:6n3 (in LYPC and PE classes). The largest significant
difference was in the total n3 content of PE, which was much
lower in FE than in HC. We also controlled for a Type I error
with the Bonferroni correction applied to alpha values of 0.10
and 0.05. A few of these tests were significant at the p<0.05
level (corrected). Thus, the difference between FE and HC
groups at baseline was evident across several lipid classes.
Discussion
In this study, the subjects with schizophrenia (FE and RE)
did not show significant differences from control subjects in
overall levels of lipids in the seven classes (i.e., PC, PE, CE,
LYPC, etc). However, differences could be detected when
individual n3 and n6 phospholipids were compared between
groups. One major finding was that the n3 phospholipid
concentrations in FE subjects were significantly different from
those in HC subjects; however, the n6 phospholipid
concentrations were similar between FE and HC groups. These
findings were taken to reflect the effects of the disease,
because the results were similar, whether we used a broader
analysis or whether we subtracted the effects of many relevant
confounders that might influence the differences, particularly
body weight, age, and gender (Table S1). Thus, our findings
suggested that alterations in n3 lipid metabolism occurred early
in the disease. In contrast, the RE subjects exhibited no
significant differences in n3 or n6 phospholipids compared to
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Figure 3.  Changes in n3 fatty acid synthesis pathways with disease progression.  Baseline levels of n3 fatty acid
concentrations were compared between healthy controls (HC) and either subjects with first episode (FE, left) or recurrent (RE, right)
schizophrenia. Green lettering indicates n3 fatty acids that were significantly increased compared to controls. Significant differences
were evaluated as described in Methods.
doi: 10.1371/journal.pone.0068717.g003
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HC subjects. This suggested that either disease progression or
previous drug treatment ameliorated the early alterations in
lipid metabolic pathways associated with schizophrenia.
Another major finding was that antipsychotic drug treatment
in the FE group caused significant changes (pre- vs. post-
treatment) in both the n3 and n6 lipid concentrations. However,
in the RE group, drug treatment caused few changes in
phospholipids. Again, these results reflected significant
differences after adjusting for body weight, age, and gender
(although age was not significantly different between RE and
HC). Thus, the results suggested that the effects of RIS and
ARI on lipid metabolism were altered, either by disease
progression or by previous treatment with drugs.
The finding that changes in lipid metabolism occurred early
in the course of schizophrenia was consistent with Horrobin’s
original hypothesis [27] and with earlier studies in red blood
cells [28] and two recent meta-analyses [29,30]. This notion
was also supported by in vivo brain studies, based on 31P
magnetic resonance (MR) spectroscopy data, which also
showed that membrane phospholipids were altered in neurons
in the prefrontal cortex of adolescent relatives that were at
genetic risk for schizophrenia [31]. The metabolomics findings
of this study were also congruent with other disparate strands
of evidence that have implicated a neurodevelopmental basis
to schizophrenia [32]. Interestingly, early disease-related
changes were previously postulated to reflect an accelerated
breakdown in membrane phospholipids that may underlie
developmentally-mediated synaptic pruning processes that
may play a role in schizophrenia [33].
We used ratios of the fatty acids that were considered the
product and precursor of each enzyme in the synthesis
pathway to evaluate potential changes in the individual steps of
the fatty acid synthesis pathways. While this method will not
provide an exact estimation of the enzymatic activity in an
individual tissue, it does allow an estimate of the average
change in enzymes from all tissues that contribute to the
plasma fatty acid pool. The results from the analysis of fatty
acid ratios suggested that FE subjects had altered elongase
activity compared to controls. The different profiles of the FE
vs. HC groups suggested that early schizophrenia was
associated with altered levels of EPA (20:5n3) and
docosahexaenoic acid (DHA; 22:6n3). This indicated that the
Δ5 desaturase activity may be altered in the FE group
compared to controls. Because the same effect was observed
in both PC and PE pathways, it is likely that the disease
caused an increase in synthesis rather than a reduction in
degradation. However, given that only the n3, and not the n6,
lipid pathways were different between FE and HC groups, it
seems clear that lipid degradation may also be a contributing
factor.
At many steps during synthesis, individual n3 and n6 fatty
acids must compete for enzymes that function in both
Figure 4.  Antipsychotic treatment effects on n3 and n6 fatty acid synthesis pathways.  Fatty acid concentrations were
compared before and after treatment in subjects with first episode (FE) or recurrent (RE) schizophrenia. Green and red lettering
represent fatty acids that showed significant increases and reductions, respectively, with treatment. Green and red arrows represent
enzymatic activities that showed significant increases and reductions, respectively, with treatment. Significant differences were
evaluated as described in Methods.
doi: 10.1371/journal.pone.0068717.g004
Lipidomics of First-Time and Chronic Schizophrenia
PLOS ONE | www.plosone.org 9 July 2013 | Volume 8 | Issue 7 | e68717
pathways. If the fatty acid synthesis pathway is taken into
consideration, in the FE group, drug treatment appeared to
affect all the fatty acids in unison. Therefore, it is possible that
all the enzymes in the pathways were upregulated, and this
caused reduced concentrations of intermediate metabolites
(precursors) in both pathways. In contrast, in the RE group,
only a few enzymes appeared to be affected by drug treatment.
Our finding that the medication-naïve FE group had
alterations in both the n3 and n6 pathways was consistent with
previous studies on lipid metabolic alterations involved in
schizophrenia [34]. For example, a previous study found that a
deficiency in n3 fatty acids was associated with decreased
dopamine concentrations and prefrontal D2 receptors [35].
Furthermore, both n3 and n6 fatty acids were found to
differentially affect the binding of serotonin (5-HT) to receptors
and transporters in rat brain [36]. It was also observed that n3
fatty acids, like DHA, could influence the turnover rate of 5-HT
in rat brain [37], and this was associated with changes in
cognitive behavior. Moreover, the cerebrospinal fluid levels of
5-hydroxyindoleacetic acid (5-HIAA, a metabolite of 5-HT) were
correlated with plasma DHA levels in healthy volunteers [38].
The present results were consistent with our previous
observations [11] that subjects with schizophrenia exhibited
reduced n3 PUFAs in PC and PE compared to controls. Our
previous study included subjects with both FE and RE
schizophrenia, but we had not separated the two groups;
therefore, those results may have been more reflective of the
FE group. The present study also demonstrated that the results
found in the FE group were independent of age and body
weight; therefore, the present results were less likely to be
biased by subject selection.
Prior studies have shown altered lipid metabolism in
schizophrenia, particularly in the PCs and PEs present in
erythrocytes [39], post-mortem brains [40], and living brain (in
vivo MR spectroscopy studies) [41]. Other studies showed that,
compared to HC subjects, phospholipid n3 fatty acids were
reduced in either RE or FE subjects [42]. The present study
demonstrated that, in the absence of medication, the n3 fatty
acids in PEs were significantly different between FE and RE
groups. However, it remains unclear whether the mechanisms
that lead to reduced n3 PUFAs early in the course of illness are
the same as those that operate in the later stages.
We also found that subjects with FE schizophrenia exhibited
more sensitivity to drug treatment than those with RE. The FE
group showed significant drug-induced changes in six n3 (PC
20:4n3, 20:5n3, 22:5n3; PE 20:5n3, 22:5n3, 22:6n3; Figure 1)
and eight n6 (PC 18:2n6, 18:3n6, 20:2n6, 20:3n6, 22:5n6; PE
20:3n6, 20:4n6, 22:5n6; Figure 2) phospholipids; the RE group
showed significant changes in only one n3 (PC22: 6n3; Figure
1) and two n6 (PC 20:2n6, 20:3n6; Figure 2) phospholipids. In
both groups, the drugs appeared to have somewhat stronger
effects on the n6 than on the n3 content of phospholipids.
Previous studies showed that treatments with other atypical
antipsychotics, olanzapine and clozapine, were associated with
increases in 20:4n6 in subjects with schizophrenia [43,44]. A
recent study by Sumiyoshi et al. [45] also demonstrated that
psychological assessments with the SAPS and SANS test
scores showed improvements in subjects with chronic
schizophrenia after treatment with atypical antipsychotic drugs
(either olanzapine or perospirone). Taken together, the results
suggested that antipsychotic drugs may play a key role in lipid
homeostasis in schizophrenia by regulating fatty acid
biosynthesis.
As part of the analysis in the present study, we accounted for
differences in age, gender, body weight, etc. among the HC,
FE, and RE groups. However, it is possible that other
environmental factors, like diet, might play an important role in
the PUFA deficits observed in schizophrenia. One study
indicated that subjects with schizophrenia tended to consume
the same or higher levels of n3 and n6 PUFAs compared to
healthy controls [46]. It is not known whether the dietary
findings in subjects with chronic schizophrenia and long
treatment histories have the same implications for subjects with
FE schizophrenia. In the present study, we assumed that any
persistent dietary differences might be reflected by differences
in BMI and body weight between groups, which were
accounted for in the covariate adjustments. Thus, we
presumed that the observations in the present study were
unlikely to be due to dietary differences alone, although this
possibility cannot be ruled out. Future investigations should
undertake a comprehensive analysis of dietary intake.
Finally, the observations in our study may be relevant to
novel treatment approaches. Recent studies have shown that
n3 supplementation may be neuroprotective. For example,
when subjects with schizophrenia received supplementation
with EPA (n3), the 5-HT-mediated amplification of platelet
aggregation was markedly enhanced [47]; this suggested that
membrane PUFA deficits might be associated with the blunted
serotonergic platelet responsivity observed in schizophrenia.
Moreover, when n3 supplementation was combined with
antipsychotic therapy, subtle MR imaging changes were
observed in subjects with FE schizophrenia [48]; this
suggested that n3 fatty acid intake may offer a therapeutic
benefit early in the course of psychosis [49]. However, our
findings suggested that n3 supplementation may not be
effective in subjects with RE schizophrenia.
Our results showed that drug treatment in the FE group
appeared to have effects on all n3 and n6 fatty acids. This
suggested that all the enzymes in the synthesis pathways were
up-regulated. However, because individual n3 and n6 fatty
acids are synthesized in competitive processes by enzymes
that function in both pathways, the drug may have increased
enzyme activity in one pathway at the expense of producing
intermediates in the other pathway. The implications of these
treatment-induced changes remain to be determined.
As discussed earlier, schizophrenia was associated with
increased inflammation [26]; the n3 and n6 fatty acids play
important roles in the balance of anti- and pro-inflammatory
processes. For example, arachidonic acid (20:4n6), which
leads to rapid production of inflammatory cytokines, competes
for the same enzymes with EPA (20:5n3), which slows the
production of inflammatory cytokines. DHA (22:6n3) also
reduces inflammatory potential. It is therefore possible that, at
least in part, the benefits and/or side effects of treatment may
be related to changes in the n3 and n6 fatty acids, and these
effects may vary for different medications. Future studies with
Lipidomics of First-Time and Chronic Schizophrenia
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larger samples and over longer periods of time are needed to
address this important question.
Supporting Information
Table S1.  Lipid concentrations were compared to
determine significant differences between controls (HC)
and patients with schizophrenia (FE and
RE).  Concentrations are shown for lipids in the major lipid
classes studied and for individual fatty acids (species) within
each lipid class.
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